Medicare proposes coverage limits for anti-anemia drugs

Medicare has proposed new restrictions on what it will cover for cancer patients prescribed anti-anemia drugs known as erythropoiesis-stimulating agents because of ties to death risks. Amgen makes Aranesp and Epogen and Johnson & Johnson makes Procrit for treating the problem, and they are expected to suffer the hardest hit if the Medicare proposal becomes final.

View Full Article in:

CNNMoney · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL